The easiest way to peek inside the inner workings of a brand-new biotech company? Check out its pipeline. For some early-stage companies, however, what would otherwise be a useful chart is better referred to as a “hypeline.”
It’s a tongue-in-cheek moniker for the overly braggadocious renderings and descriptions of the drug candidates and therapies a new company hopes to bring to market. A normal pipeline might include just one column for preclinical studies. A “hypeline,” in contrast, will include milestones above and beyond the three traditional phases of clinical trials. Others might conveniently forget to represent later-stage clinical trials, like Inozyme, or find creative ways to represent discovery work, like Mersana did.